- 日
- 関
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/05/28 11:42:13」(JST)
[Wiki en表示]
Rokitamycin
|
Systematic (IUPAC) name |
(2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6S)-6-{[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-2,4-dimethyl-4-propoxyoxan-3-yl butanoate |
Clinical data |
AHFS/Drugs.com |
International Drug Names |
Identifiers |
CAS Registry Number
|
74014-51-0 N |
ATC code
|
J01FA12 |
PubChem |
CID 5282211 |
ChemSpider |
4445397 Y |
UNII |
ZPT03UEM0E Y |
ChEMBL |
CHEMBL1908350 N |
Chemical data |
Formula |
C42H71NO14 |
Molecular mass
|
827.999 g/mol |
SMILES
- O=CC[C@H]3C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@H](OC(=O)C[C@@H](O)[C@H](OC)[C@H]3O[C@@H]2O[C@@H]([C@@H](O[C@@H]1O[C@H]([C@H](OC(=O)CCC)[C@](OC(=O)CC)(C1)C)C)[C@H](N(C)C)[C@H]2O)C)C
|
InChI
-
InChI=1S/C42H69NO15/c1-11-16-32(48)55-40-27(6)53-34(23-42(40,7)58-31(47)12-2)56-37-26(5)54-41(36(50)35(37)43(8)9)57-38-28(19-20-44)21-24(3)29(45)18-15-13-14-17-25(4)52-33(49)22-30(46)39(38)51-10/h13-15,18,20,24-30,34-41,45-46,50H,11-12,16-17,19,21-23H2,1-10H3/b14-13+,18-15+/t24-,25-,26-,27+,28+,29+,30-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1 Y
Key:VYWWNRMSAPEJLS-MDWYKHENSA-N Y
|
Physical data |
Melting point |
116 °C (241 °F) |
Solubility in water
|
Insoluble in water; Very soluble in chloroform and methanol; Almost completely (>99.5 %) in ethanol and acetonitrile. mg/mL (20 °C) |
N (what is this?) (verify) |
Rokitamycin is a macrolide antibiotic. Synthesized from strains of Streptomyces kitasatoensis.
Antibacterials: protein synthesis inhibitors (J01A, J01B, J01F, J01G, QJ01XQ)
|
|
30S |
Aminoglycosides
(initiation inhibitors) |
-mycin (Streptomyces) |
- Streptomycin#
- Dihydrostreptomycin
- Neomycin#
- Framycetin
- Paromomycin
- Ribostamycin
- Kanamycin#
- Amikacin
- Arbekacin
- Bekanamycin
- Dibekacin
- Tobramycin
- Spectinomycin#
- Hygromycin B
|
|
-micin (Micromonospora) |
- Gentamicin#
- Netilmicin
- Sisomicin
- Isepamicin
|
|
|
Tetracycline antibiotics
(tRNA binding) |
Tetracyclines |
- Doxycycline#
- Chlortetracycline
- Clomocycline
- Demeclocycline
- Lymecycline
- Meclocycline
- Metacycline
- Minocycline
- Oxytetracycline
- Penimepicycline
- Rolitetracycline
- Tetracycline
|
|
Glycylcyclines |
|
|
|
|
50S |
Oxazolidinone
(initiation inhibitors) |
- Eperezolid
- Linezolid
- Posizolid
- Radezolid
- Ranbezolid
- Sutezolid
- Tedizolid
|
|
Peptidyl transferase |
Amphenicols |
- Chloramphenicol#
- Azidamfenicol
- Thiamphenicol
- Florfenicol
|
|
Pleuromutilins |
- Retapamulin
- Tiamulin
- Valnemulin
|
|
|
MLS (transpeptidation/translocation) |
Macrolides |
- Azithromycin#
- Clarithromycin
- Dirithromycin
- Erythromycin#
- Flurithromycin
- Josamycin
- Midecamycin
- Miocamycin
- Oleandomycin
- Rokitamycin
- Roxithromycin
- Spiramycin
- Troleandomycin
- Tylosin
- Ketolides
- Telithromycin
- Cethromycin
- Solithromycin†
|
|
Lincosamides |
- Clindamycin#
- Lincomycin
- Pirlimycin
|
|
Streptogramins |
- Pristinamycin
- Quinupristin/dalfopristin
- Virginiamycin
|
|
|
|
EF-G |
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Index of bacterial disease
|
|
Description |
|
|
Disease |
- Gram-positive firmicutes
- Gram-positive actinobacteria
- Gram-negative proteobacteria
- Gram-negative non-proteobacteria
- Cholera
- Tuberculosis
|
|
Treatment |
- Antibiotics
- cell wall
- nucleic acid
- mycobacteria
- protein synthesis
- other
- Antibodies
- Vaccines
|
|
|
External links
- Recent Publications on Rokitamycin
English Journal
- Amebic meningoencephalitides and keratitis: challenges in diagnosis and treatment.
- Visvesvara GS.SourceCenters for Disease Control and Prevention, Atlanta, Georgia 30333, USA. gsv1@cdc.gov
- Current opinion in infectious diseases.Curr Opin Infect Dis.2010 Dec;23(6):590-4.
- PURPOSE OF REVIEW: Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri, although free-living amebae, also cause devastating diseases in humans leading to death. Acanthamoeba spp. and B. mandrillaris cause granulomatous amebic encephalitis, cutaneous and nasopharyngeal as well as dissem
- PMID 20802332
- Influence of chitosan glutamate on the in vivo intranasal absorption of rokitamycin from microspheres.
- Gavini E, Rassu G, Ferraro L, Generosi A, Rau JV, Brunetti A, Giunchedi P, Dalpiaz A.SourceDepartment of Drug Sciences, University of Sassari, Sassari 07100, Italy.
- Journal of pharmaceutical sciences.J Pharm Sci.2010 Oct 29. [Epub ahead of print]
- Intranasal delivery is an alternative method to target therapeutics to the central nervous system. In the present study, chitosan glutamate (CG)-based mucoadhesive microspheres containing rokitamycin (RK) were prepared by spray-drying and in vitro characterization. Moreover, the influence of CG on R
- PMID 21038406
Japanese Journal
- Protective Effects of Clarithromycin, a Lipophilic 14-membered Macrolide, on Hemolysis Induced by Lysophosphatidylcholine in Human Erythrocytes
- 試験管内でセレクションされたマクロライド耐性 Mycoplasma pneumoniae について : アジスロマイシンとロキタマイシンにおける耐性菌セレクションの比較
- 日本マイコプラズマ学会雑誌 = Japanese Journal of Mycoplasmology 37, 55-58, 2011-03-31
- NAID 10029813475
- Rokitamycin Induces a Mitochondrial Defect and Caspase-Dependent Apoptosis in Human T-Cell Leukemia Jurkat Cells
Related Links
- Rokitamycin [RKM] ロキタマイシン, マクロライド系 1. 商品名 先発品 リカマイシンドライシロップ200 【旭化成ファーマ】 リカマイシン錠100mg 【旭化成ファーマ】 2. 日本における発売年 1986(昭和61)年 3. 特長 殺菌作用を有するマクロ ...
- Rokitamycin(TMS‐19‐Q DS200)の耳鼻咽喉科領域感染症に対する臨床評価 Clinical evaluation of ... マクロライド系抗生物質であるロキタマイシンドライシロップの新しい高含量製剤 (TMS-19-Q DS 200) を当院にて耳鼻咽喉科 ...
Related Pictures
★リンクテーブル★
[★]
- 英
- macrolide antibiotic macrolide antibiotics, macrolides, MLs
- 同
- マクロライド系抗生物質 ←厳密には違うが、多くの人が間違って使っている
- 関
- 抗菌薬
特徴
- 抗菌スペクトルが広い
- 静菌的に作用
- 大きな環状構造を有する。14員環-16員環
- タンパク質合成阻害薬
- 抗生物質としての作用の他に、抗炎症作用を有するらしい
- 炎症の抑制 ex.びまん性汎細気管支炎
構造
- http://www.sigmaaldrich.com/life-science/life-science-catalog/product-catalog.html?TablePage=14572877
- Macrolide antibiotics contain a many-membered lactone ring (14-membered rings for erythromycin and clarithromycin and a 15-membered ring for azithromycin) to which are attached one or more deoxy sugars. Clarithromycin differs from erythromycin only by methylation of the hydroxyl group at the 6 position, and azithromycin differs by the addition of a methyl-substituted nitrogen atom into the lactone ring. These structural modifications improve acid stability and tissue penetration and broaden the spectrum of activity.(GOO. chapter 46)
作用機序
- inhibit bacterial protein synthesis by reacting with the 50s ribosomal subunit and preventing the release of the uncharged tRNA.
薬理作用
動態
抗菌スペクトル
- ペニシリンより広い抗菌スペクトル
- グラム陽性球菌、グラム陰性球菌、グラム陰性桿菌、スピロヘータ、一部のリケッチア、ウイルス
適応
- マイコプラズマ肺炎、クラミジア感染症、カンピロバクター腸炎、レジオネラ症
- びまん性汎細気管支炎:14員環マクロライドのみ
- URIs, pneumonias, STD
注意
禁忌
副作用
- 悪心、嘔吐、消化器の蠕動を促進
- テオフィリン
- 喘息の治療薬。CYP3A4で代謝される。中毒域と治療域がちかいので注意する
マクロライド系抗菌薬
14員環
15員環
16員環
14員環 (ケトライド系抗菌薬)
有効性 (SMB.147)
- ○:殺菌的、△静菌的
[★]
- 英
- rokitamycin, RKM
- 商
- リカマイシン
- 関
- 抗菌薬